ArticleThe New England journal of medicine2016
I-SPY 2--A Glimpse of the Future of Phase 2 Drug Development?
Article in The New England journal of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sequential analysis in neonatal research-systematic review.European journal of pediatrics · 2018Pooled it
- Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.Nature medicine · 2024Trial
- Establishment and evaluation of novel prognostic biomarkers based on systemic coagulation-inflammation index and related genes in breast cancer.Frontiers in immunology · 2026Article
- Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond.Breast cancer (Dove Medical Press) · 2025Review
- A platform trial approach to proof-of-concept (POC) studies in autism spectrum disorder: Autism spectrum POC initiative (ASPI).Contemporary clinical trials communications · 2023Article
- New Insights into Clinical and Mechanistic Heterogeneity of the Acute Respiratory Distress Syndrome: Summary of the Aspen Lung Conference 2021.American journal of respiratory cell and molecular biology · 2022Article
- Development and Validation of a Nomogram to Predict the Probability of Breast Cancer Pathologic Complete Response after Neoadjuvant Chemotherapy: A Retrospective Cohort Study.Frontiers in surgery · 2022Article
- Clinical trial design during and beyond the pandemic: the I-SPY COVID trial.Nature medicine · 2022Article
- Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.NPJ breast cancer · 2021Article
- A nomogram based on clinicopathological features and serological indicators predicting breast pathologic complete response of neoadjuvant chemotherapy in breast cancer.Scientific reports · 2021Article
- PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial.JAMIA open · 2021Article
- The effects of releasing early results from ongoing clinical trials.Nature communications · 2021Article
- The world is waiting, use sequential analysis and get us the evidence-based treatment we need for COVID-19.The Libyan journal of medicine · 2020Review
- Progress in adjuvant systemic therapy for breast cancer.Nature reviews. Clinical oncology · 2019Review
- The Role of Public-Private Partnerships in Catalyzing the Critical Path.Clinical and translational science · 2017Review
- Precision medicine needs randomized clinical trials.Nature reviews. Clinical oncology · 2017Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27406345What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.